ISAN CHEN - 17 Sep 2021 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Director
Signature
/s/ John Healy, Attorney-in Fact
Issuer symbol
TYRA
Transactions as of
17 Sep 2021
Net transactions value
$0
Form type
4
Filing time
17 Sep 2021, 16:42:49 UTC
Previous filing
14 Sep 2021
Next filing
15 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Conversion of derivative security +61,444 +47% 192,783 17 Sep 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Series A Preferred Stock Conversion of derivative security $0 -16,366 -100% $0.000000* 0 17 Sep 2021 Common Stock 42,509 Direct F1
transaction TYRA Series B Preferred Stock Conversion of derivative security $0 -7,290 -100% $0.000000* 0 17 Sep 2021 Common Stock 18,935 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2 Includes 37,105 shares subject to repurchase by us, which are subject to vesting.